Dashboard
1
High Management Efficiency with a high ROE of 12.49%
2
Company has very low debt and has enough cash to service the debt requirements
3
The company has declared Negative results for the last 3 consecutive quarters
4
With ROE of 6.41%, it has a very attractive valuation with a 0.97 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
JPY 865,731 Million (Mid Cap)
15.00
NA
0.03%
-0.01
5.56%
1.12
Revenue and Profits:
Net Sales:
127,536 Million
(Quarterly Results - Jun 2025)
Net Profit:
17,631 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
25.09%
0%
25.09%
6 Months
41.19%
0%
41.19%
1 Year
26.62%
0%
26.62%
2 Years
-14.59%
0%
-14.59%
3 Years
-36.54%
0%
-36.54%
4 Years
-20.7%
0%
-20.7%
5 Years
-32.2%
0%
-32.2%
Ono Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.73%
EBIT Growth (5y)
-4.35%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.09
Sales to Capital Employed (avg)
0.57
Tax Ratio
15.48%
Dividend Payout Ratio
75.08%
Pledged Shares
0
Institutional Holding
0.04%
ROCE (avg)
20.45%
ROE (avg)
12.49%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
0.97
EV to EBIT
10.81
EV to EBITDA
7.59
EV to Capital Employed
0.96
EV to Sales
1.41
PEG Ratio
NA
Dividend Yield
0.03%
ROCE (Latest)
8.91%
ROE (Latest)
6.41%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.04%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
127,536.00
117,675.00
8.38%
Operating Profit (PBDIT) excl Other Income
32,423.00
35,640.00
-9.03%
Interest
773.00
75.00
930.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
17,631.00
24,835.00
-29.01%
Operating Profit Margin (Excl OI)
181.80%
265.70%
-8.39%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 8.38% vs -1.95% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -29.01% vs -21.95% in Jun 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
486,871.00
502,672.00
-3.14%
Operating Profit (PBDIT) excl Other Income
90,278.00
181,701.00
-50.32%
Interest
1,635.00
105.00
1,457.14%
Exceptional Items
-1,645.00
-137.00
-1,100.73%
Consolidate Net Profit
50,166.00
128,040.00
-60.82%
Operating Profit Margin (Excl OI)
130.20%
325.40%
-19.52%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is -3.14% vs 12.41% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is -60.82% vs 13.40% in Mar 2024
About Ono Pharmaceutical Co., Ltd. 
Ono Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






